Connor, Clark & Lunn Investment Management (CC&L)
AKBA icon

Connor, Clark & Lunn Investment Management (CC&L)’s Akebia Therapeutics AKBA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.7K Sell
22,575
-251,856
-92% -$300K ﹤0.01% 1615
2026
Q1 		$381K Sell
274,431
-479,475
-64% -$659K ﹤0.01% 1361
2025
Q4 		$1.21M Sell
753,906
-266,762
-26% -$559K ﹤0.01% 1074
2025
Q3 		$2.79M Sell
1,020,668
-160,091
-14% -$533K 0.01% 749
2025
Q2 		$4.3M Buy
1,180,759
+210,925
+22% +$580K 0.02% 623
2025
Q1 		$1.86M Sell
969,834
-57,062
-6% -$116K 0.01% 753
2024
Q4 		$1.95M Sell
1,026,896
-19,795
-2% -$34.4K 0.01% 733
2024
Q3 		$1.38M Buy
1,046,691
+632
+0.1% +$844 0.01% 779
2024
Q2 		$1.07M Buy
1,046,059
+1,588
+0.2% +$1.96K ﹤0.01% 830
2024
Q1 		$1.91M Buy
1,044,471
+424,152
+68% +$678K 0.01% 685
2023
Q4 		$769K Sell
620,319
-3,823
-0.6% -$3.9K ﹤0.01% 936
2023
Q3 		$712K Buy
624,142
+9,264
+2% +$11.9K ﹤0.01% 931
2023
Q2 		$563K Buy
614,878
+311,901
+103% +$301K ﹤0.01% 959
2023
Q1 		$170K Buy
302,977
+182,924
+152% +$140K ﹤0.01% 1114
2022
Q4 		$69.3K Sell
120,053
-390,049
-76% -$122K ﹤0.01% 1134
2022
Q3 		$161K Buy
510,102
+283,332
+125% +$111K ﹤0.01% 1011
2022
Q2 		$80K Sell
226,770
-244,911
-52% -$103K ﹤0.01% 995
2022
Q1 		$339K Buy
471,681
+69,265
+17% +$148K ﹤0.01% 849
2021
Q4 		$909K Sell
402,416
-28,255
-7% -$77K ﹤0.01% 694
2021
Q3 		$1.24M Buy
430,671
+219,381
+104% +$626K 0.01% 603
2021
Q2 		$801K Buy
211,290
+120,633
+133% +$406K ﹤0.01% 704
2021
Q1 		$307K Buy
+90,657
New +$327K ﹤0.01% 860
2017
Q4 		– Sell
-13,755
Closed -$271K – 770
2017
Q3 		$271K Sell
13,755
-30,045
-69% -$462K ﹤0.01% 716
2017
Q2 		$629K Buy
+43,800
New +$555K ﹤0.01% 564
2016
Q3 		– Sell
-16,100
Closed -$120K – 832
2016
Q2 		$120K Sell
16,100
-52,100
-76% -$455K ﹤0.01% 788
2016
Q1 		$614K Sell
68,200
-29,725
-30% -$241K ﹤0.01% 537
2015
Q4 		$1.26M Buy
97,925
+8,500
+10% +$86.7K 0.01% 409
2015
Q3 		$864K Buy
89,425
+52,525
+142% +$482K 0.01% 432
2015
Q2 		$380K Buy
36,900
+13,000
+54% +$111K ﹤0.01% 465
2015
Q1 		$266K Buy
23,900
+10,200
+74% +$109K ﹤0.01% 470
2014
Q4 		$159K Buy
+13,700
New +$196K ﹤0.01% 539

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Connor, Clark & Lunn Investment Management (CC&L)'s AKBA Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Akebia Therapeutics (AKBA) stake by 92% in Q2 2026, selling an estimated $300K and leaving 22,575 shares worth $25.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AKBA in Q4 2014 and has held it in 31 quarters since. The position peaked at $4.3M in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 22,575 shares of Akebia Therapeutics worth $25.7K as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 251,856 Akebia Therapeutics shares in Q2 2026, an estimated $300K.
  • Akebia Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1615 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Akebia Therapeutics in Q4 2014 and has held it in 31 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Akebia Therapeutics position peaked at $4.3M in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.